Trial Spotlight

FORAGER-1; NCT05614739

A Phase 1, Open-label, Multicenter Study of Vepugratinib in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer with FGFR3 Alterations^a

Trial Spotlight

SUNRAY-01; NCT06119581

A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression^a

Breast

Mechanism of Action	Molecule	Trial Identifier	Phase	Status
CDK4/6 Inhibitor	Abemaciclib	NCT02107703; MONARCH 2	3	Active, not recruiting
CDK4/6 Inhibitor	Abemaciclib	NCT02246621; MONARCH 3	3	Active, not recruiting
CDK4/6 Inhibitor	Abemaciclib	NCT03155997; monarchE	3	Active, not recruiting
CDK4/6 Inhibitor	Abemaciclib	NCT05169567; postMONARCH	3	Active, not recruiting
FRα Antibody-Drug Conjugate	LY4170156	NCT06400472	1	Recruiting
Nectin-4 Antibody-Drug Conjugate 1	LY4101174	NCT06238479; EXCEED	1	Recruiting
Nectin-4 Antibody-Drug Conjugate 2	LY4052031	NCT06465069; NEXUS-01	1	Recruiting
Pan-Mutant Selective PI3Kα Inhibitor	LY4064809 (STX-478)	NCT05768139	1	Recruiting
PTK7 Antibody-Drug Conjugate	LY4175408	NCT07046923	1	Recruiting
Selective Estrogen Receptor Degrader	Imlunestrant	NCT04188548; EMBER	1	Active, not recruiting
Selective Estrogen Receptor Degrader	Imlunestrant	NCT04975308; EMBER-3	3	Active, not recruiting
Selective Estrogen Receptor Degrader	Imlunestrant	NCT05514054; EMBER-4	3	Recruiting

Gastrointestinal

Mechanism of Action	Molecule	Trial Identifier	Phase	Status
FRα Antibody-Drug Conjugate	LY4170156	NCT06400472	1	Recruiting
KRAS G12C Inhibitor	Olomorasib	NCT04956640	2	Recruiting
KRAS G12D Inhibitor	LY3962673	NCT06586515; MOONRAY-01	1	Recruiting
Nectin-4 Antibody-Drug Conjugate 1	LY4101174	NCT06238479; EXCEED	1	Recruiting
Nectin-4 Antibody-Drug Conjugate 2	LY4052031	NCT06465069; NEXUS-01	1	Recruiting
Pan-KRAS Inhibitor	LY4066434	NCT06607185	1	Recruiting

Genitourinary

Mechanism of Action	Molecule	Trial Identifier	Phase	Status
FGFR3 Inhibitor	Vepugratinib	NCT05614739; FORAGER-1	1	Recruiting
Nectin-4 Antibody-Drug Conjugate 1	LY4101174	NCT06238479; EXCEED	1	Recruiting
Nectin-4 Antibody-Drug Conjugate 2	LY4052031	NCT06465069; NEXUS-01	1	Recruiting
Prostate-Specific Membrane Antigen (PSMA) Radioligand	[Ac-225]-PSMA-62	NCT06229366; ACCEL	1	Recruiting

Gynecologic

Mechanism of Action	Molecule	Trial Identifier	Phase	Status
FRα Antibody-Drug Conjugate	LY4170156	NCT06400472	1	Recruiting
Nectin-4 Antibody-Drug Conjugate 1	LY4101174	NCT06238479; EXCEED	1	Recruiting
Nectin-4 Antibody-Drug Conjugate 2	LY4052031	NCT06465069; NEXUS-01	1	Recruiting
PTK7 Antibody-Drug Conjugate	LY4175408	NCT07046923	1	Recruiting
Selective Estrogen Receptor Degrader	Imlunestrant	NCT04188548; EMBER	1	Active, not recruiting

Hematologic

Mechanism of Action	Molecule	Trial Identifier	Phase	Status
BAFF-R T-Cell Engager	LY4152199	PRECLINICAL
BTK Inhibitor	Pirtobrutinib	NCT03740529; BRUIN	2	Active, not recruiting
BTK Inhibitor	Pirtobrutinib	NCT04662255; BRUIN MCL-321	3	Active, not recruiting
BTK Inhibitor	Pirtobrutinib	NCT04666038; BRUIN CLL-321	3	Active, not recruiting
BTK Inhibitor	Pirtobrutinib	NCT04965493; BRUIN CLL-322	3	Active, not recruiting
BTK Inhibitor	Pirtobrutinib	NCT05023980; BRUIN CLL-313	3	Active, not recruiting
BTK Inhibitor	Pirtobrutinib	NCT05254743; BRUIN CLL-314	3	Active, not recruiting
BTK Inhibitor	Pirtobrutinib	NCT06588478; BRUIN CLL-211	2	Recruiting

Lung

Mechanism of Action	Molecule	Trial Identifier	Phase	Status
FRα Antibody-Drug Conjugate	LY4170156	NCT06400472	1	Recruiting
KRAS G12C Inhibitor	Olomorasib	NCT04956640	2	Recruiting
KRAS G12C Inhibitor	Olomorasib	NCT06119581; SUNRAY-01	3	Recruiting
KRAS G12C Inhibitor	Olomorasib	NCT06890598; SUNRAY-02	3	Recruiting
KRAS G12D Inhibitor	LY3962673	NCT06586515; MOONRAY-01	1	Recruiting
Nectin-4 Antibody-Drug Conjugate 1	LY4101174	NCT06238479; EXCEED	1	Recruiting
Nectin-4 Antibody-Drug Conjugate 2	LY4052031	NCT06465069; NEXUS-01	1	Recruiting
Pan-KRAS Inhibitor	LY4066434	NCT06607185	1	Recruiting
PTK7 Antibody-Drug Conjugate	LY4175408	NCT07046923	1	Recruiting
RET Inhibitor	Selpercatinib	NCT04194944; LIBRETTO-431	3	Active, not recruiting
RET Inhibitor	Selpercatinib	NCT04819100; LIBRETTO-432	3	Active, not recruiting
SMARCA2 (BRM) Inhibitor	LY4050784	NCT06561685	1	Recruiting
VEGF Receptor-2 Antagonist	Ramucirumab	NCT02411448; RELAY	3	Active, not recruiting

Other Solid Tumors

Mechanism of Action	Molecule	Trial Identifier	Phase	Status
¹⁷⁷Lu-FAP	LY4337713	PRECLINICAL
CDK4/6 Inhibitor	Abemaciclib	NCT04238819	2	Active, not recruiting
CDK4/6 Inhibitor	Abemaciclib	NCT06413706	2	Recruiting
FGFR3 Inhibitor	Vepugratinib	NCT05614739; FORAGER-1	1	Recruiting
KRAS G12C Inhibitor	Olomorasib	NCT04956640	2	Recruiting
KRAS G12D Inhibitor	LY3962673	NCT06586515; MOONRAY-01	1	Recruiting
Nectin-4 Antibody-Drug Conjugate 1	LY4101174	NCT06238479; EXCEED	1	Recruiting
Nectin-4 Antibody-Drug Conjugate 2	LY4052031	NCT06465069; NEXUS-01	1	Recruiting
Pan-KRAS Inhibitor	LY4066434	NCT06607185	1	Recruiting
Pan-Mutant Selective PI3Kα Inhibitor	LY4064809 (STX-478)	NCT05768139	1	Recruiting
PTK7 Antibody-Drug Conjugate	LY4175408	NCT07046923	1	Recruiting
RET Inhibitor	Selpercatinib	NCT03157128; LIBRETTO-001	2	Active, not recruiting
RET Inhibitor	Selpercatinib	NCT03899792; LIBRETTO-121	2	Active, not recruiting
SMARCA2 (BRM) Inhibitor	LY4050784	NCT06561685	1	Recruiting

Sarcoma

Mechanism of Action	Molecule	Trial Identifier	Phase	Status
CDK4/6 Inhibitor	Abemaciclib	NCT05440786; CAMPFIRE	2	Active, not recruiting
VEGF Receptor-2 Antagonist	Ramucirumab	NCT04145349; CAMPFIRE	2	Active, not recruiting

Thyroid

Mechanism of Action	Molecule	Trial Identifier	Phase	Status
RET Inhibitor	Selpercatinib	NCT03157128; LIBRETTO-001	2	Active, not recruiting
RET Inhibitor	Selpercatinib	NCT04211337; LIBRETTO-531	3	Active, not recruiting